RESUMO
No disponible
Assuntos
Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Idoso , Idoso de 80 Anos ou mais , Humanos , Fibrinolíticos/uso terapêutico , Terapia Trombolítica , Isquemia/tratamento farmacológico , Perna (Membro)/irrigação sanguínea , Índice de Gravidade de DoençaRESUMO
Prevention and treatment of the venous thromboembolic phenomena should be modified in a near future. The arrival of two new classes of anticoagulants: antifactor Xa and anti-factor IIa, opens a new perspective in an area in which low molecular weight heparins and oral anticoagulants have the exclusivity. Fondaparinux has the approval for its introduction into the market as a maximum representative of this group and has begun to be used. Among the direct antithrombotics we find melagatran and its oral form, ximelagatran, that opts to be the substitute of oral anticoagulants.
Assuntos
Antitrombina III/uso terapêutico , Antitrombinas/uso terapêutico , Azetidinas/uso terapêutico , Benzilaminas/uso terapêutico , Fibrinolíticos/uso terapêutico , Polissacarídeos/uso terapêutico , Trombose Venosa/tratamento farmacológico , Fondaparinux , Previsões , HumanosRESUMO
La prevención y el tratamiento de los fenómenos tromboembólicos venosos deberán modificarse en un futuro próximo. La llegada de dos nuevas clases de anticoagulantes: antifactor Xa y antifactor IIa abren una nueva perspectiva en un terreno en el que las heparinas de bajo peso molecular y los anticoagulantes orales tienen la exclusividad. Fondaparinux tiene el visto bueno para su introducción en el mercado como máximo representante de este grupo y empieza a ser utilizado. Entre los antitrombóticos directos existe el melagatrán y su forma oral, el ximelagatrán, que opta a ser el sustituto de los anticoagulantes orales
Prevention and treatment of the venous thromboembolic phenomena should be modified in a near future. The arrival of two new classes of anticoagulants: antifactor Xa and anti-factor IIa, opens a new perspective in an area in which low molecular weight heparins and oral anticoagulants have the exclusivity. Fondaparinux has the approval for its introduction into the market as a maximum representative of this group and has begun to be used. Among the direct antithrombotics we find melagatran and its oral form, ximelagatran, that opts to be the substitute of oral anticoagulants
Assuntos
Humanos , Trombose Venosa/tratamento farmacológico , Anticoagulantes/farmacocinética , Heparina de Baixo Peso Molecular/farmacocinética , Fibrinolíticos/farmacocinéticaRESUMO
Hypertension can complicate the course of neurofibromatosis. When it appears in adulthood (after 18 years of age) it is usually due to pheochromocytoma, but in children the cause is a stenotic lesion of the renal arteries or the suprarenal aorta. Its treatment follows the general principles used in the treatment of the more common forms of renovascular hypertension. We report four patients that developed renovascular hypertension after being diagnosed of neurofibromatosis, they had different localizations of the stenotic lesion, and the diverse types of surgical treatment are analyzed.
